Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Clements, Debbie ^a   Dongre, Arundhati ^a   Krymskaya, Vera P ^b   Johnson, Simon R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; FIBROBLAST ACTIVATION PROTEIN; FIBROBLAST SURFACE PROTEIN; MEMBRANE PROTEIN; S6 KINASE; STROMAL CELL DERIVED FACTOR 1; TUBERIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL AGGREGATION; CELL CULTURE; CELL INTERACTION; CELL ISOLATION; CELL MIGRATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; CHEMOTAXIS ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LUNG CYST; LYMPHANGIOLEIOMYOMATOSIS; MESENCHYME CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRESS FIBER; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; LUNG; MESENCHYMAL STROMA CELL; PATHOLOGY;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUNG; LYMPHANGIOLEIOMYOMATOSIS; MESENCHYMAL STROMAL CELLS; MICE;

EID: 84929376707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126025     Document Type: Article

References (35)

1. Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004; 59 (9) : 800-3. PMID: 15333859
2. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006; 27 (5) : 1056-65. PMID: 16707400
3. Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997; 28 (9) : 1071-8. PMID: 9308732
4. Chilosi M, Pea M, Martignoni G, Brunelli M, Gobbo S, Poletti V, et al. Cathepsin-K expression in pulmonary lymphangioleiomyomatosis. Mod Pathol. 2009; 22: 161-6. doi: 10.1038/modpathol.2008.189 PMID: 19060845
5. Finlay G. The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol. 2004; 286 (4) : L690-3. PMID: 15003933
6. Pea M, Martignoni G, Bonetti F, Zamboni G, Colombari C, Manfrin E, et al. Tumors characterized by the presence of HMB45-positive perivascular epithelioid cell (PEC) -A novel entity in surgical pathology. Electronic Journal of Pathology & Histology. 1997; 3 (2) : 28-40. doi: 10.1016/j.exer.2014.03.001 PMID: 24631337
7. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in Tuberous Sclerosis and sporadic Lymphangiomyomatosis. Am J Respir Crit Care Med. 2001; 164 (8) : 1537-397. PMID: 11704609
8. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005; 24 (50) : 7475-81. PMID: 16288294
9. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr., Wang J-a, Kumaki F, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. PNAS. 2004; 101 (50) : 17462-7. PMID: 15583138
10. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes, Chromosomes & Cancer. 2003; 38 (4) : 376-81.
11. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 1999; 21 (3) : 327-36. PMID: 10460750
12. Matsui K, Takeda K, Yu ZX, Valencia J, Travis WD, Moss J, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med. 2000; 161 (3 Pt 1) : 1002-9. PMID: 10712355
13. Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res. 2007; 67 (21) : 10573-81. PMID: 17975002
14. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med. 2001; 163 (1) : 253-8. PMID: 11208653
15. Badri KR, Gao L, Hyjek E, Schuger N, Schuger L, Qin W, et al. Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2013; 187 (6) : 663-5. PMID: 23504366
16. Zhang J, Liu J. Tumor stroma as targets for cancer therapy. Pharmacol Ther. 2013; 137 (2) : 200-15. doi: 10.1016/j.pharmthera.2012.10.003 PMID: 23064233
17. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol. 2011; 43 (7) : 1045-51. doi: 10.1016/j.biocel.2011.01.023 PMID: 21300172
18. Fearon DT. The carcinoma-associated fibroblast expressing Fibroblast Activation Protein and escape from immune surveillance. Cancer Immunol Res. 2014; 2 (3) : 187-93. doi: 10.1158/2326-6066.CIR-14-0002 PMID: 24778314
19. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and Tamoxifen stimulate lymphangiomyomatosisassociated angiomyolipoma cell growth and activate both genomic and non-genomic signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2003; 286 (4) : L694-700. PMID: 12922981
20. Henderson N, Markwick LJ, Elshaw SR, Freyer AM, Knox AJ, Johnson SR. Collagen I and thrombin activate MMP-2 by MMP-14-dependent and-independent pathways: implications for airway smooth muscle migration. Am J Physiol Lung Cell Mol Physiol. 2007; 292 (4) : L1030-8. PMID: 17189319
21. Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, et al. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med. 2012; 4 (154) : 154ra34.
22. Johnson SR, Clelland CA, Ronan J, Tattersfield AE, Knox AJ. The TSC-2 product tuberin is expressed in lymphangioleiomyomatosis and angiomyolipoma. Histopathology. 2002; 40 (5) : 458-63. PMID: 12010366
23. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol. 1995; 130 (2) : 393-405. PMID: 7615639
24. Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, et al. Characterization of Fibroblast-Specific Protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171 (8) : 899-907. PMID: 15618458
25. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010; 176 (1) : 85-97. doi: 10.2353/ajpath.2010.090517 PMID: 20008127
26. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of Fibroblast Activation Protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994; 91 (12) : 5657-61. PMID: 7911242
27. Valencia JC, Steagall WK, Zhang Y, Fetsch P, Abati A, Tsukada K, et al. Antibody alphaPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules. Chest. 2014; 147 (3) : 771-7.
28. Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2013; 153 (4) : 840-54. doi: 10. 1016/j.cell.2013.04.023 PMID: 23663782
29. Udagawa T, Puder M, Wood M, Schaefer BC, D'Amato RJ. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J. 2006; 20 (1) : 95-102. PMID: 16394272
30. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008; 3 (3) : 301-13. doi: 10.1016/j.stem.2008. 07.003 PMID: 18786417
31. Clements D, Markwick LJ, Puri N, Johnson SR. Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma. J Immunol. 2010; 185 (3) : 1812-21. doi: 10.4049/jimmunol.0902149 PMID: 20585037
32. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013; 49 (1) : 219-30. doi: 10. 1016/j.ejca.2012.05.005 PMID: 22683307
33. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009; 23 (1) : 43-52. doi: 10.1038/leu.2008.299 PMID: 18987663
34. Ruiz EJ, Oeztuerk-Winder F, Ventura JJ. A paracrine network regulates the cross-talk between human lung stem cells and the stroma. Nat Commun. 2014; 5: 3175. doi: 10.1038/ncomms4175 PMID: 24430801
35. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008; 123 (10) : 2229-38. doi: 10.1002/ijc.23925 PMID: 18777559